Description
Livagen is a synthetic tetrapeptide bioregulator, developed by Professor Vladimir Khavinson from liver tissue polypeptide extracts. It belongs to the same Khavinson specialty research peptide class as Epithalon and Cardiogen, operating through the same intranuclear DNA-binding mechanism. But with a distinct tissue target profile spanning lymphocytes, hepatocytes, and gastrointestinal tissue. Its primary research interest centers on chromatin decondensation. Livagen is studied for its capacity to induce deheterochromatinization of densely packed chromatin, particularly ribosomal gene regions, restoring transcriptional access to genes that become silenced through heterochromatin formation in aged cell populations.
Chemical Information
- Chemical Name: Livagen (Khavinson liver-derived tripeptide bioregulator)
- Also Known As: Livagen peptide complex
- Compound Class: Short-chain synthetic tripeptide; tissue-specific epigenetic bioregulator (Khavinson series)
- Sequence: Not established in public literature
- Molecular Formula: Not established in public literature
- Molecular Weight: Not established in public literature (consistent with the broader Khavinson class of low molecular weight peptides, <10,000 Da)
- CAS Number: Not established in public literature
Applications
- Hepatocyte-specific gene regulation research. Livagen is modeled on liver tissue and is proposed to act via direct peptide-DNA interaction within hepatocyte nuclei, modulating expression of genes involved in liver cell metabolism and regeneration — a mechanism shared with other tissue-targeted Khavinson bioregulators such as Cartalax (chondrocytes), Cardiogen (cardiomyocytes), and Chonluten (bronchial epithelium)
- Liver regeneration and metabolic stress research. Published Khavinson-network literature on tissue-specific bioregulators has examined regenerative and stress-resistance gene programs in matched organ systems; Livagen is studied within this framework for hepatocyte-directed effects
- Cross-tissue bioregulator specificity research. Because Livagen is proposed to share its intranuclear DNA-interaction mechanism with other short-chain Khavinson peptides, it is used alongside tissue-matched and mismatched bioregulators to test whether reported gene-regulatory effects are tissue-restricted or tissue-general
- Note on evidence base: Published data on Livagen are concentrated in Russian-language and Khavinson-network literature and are largely preclinical; independent Western replication is limited
Storage and Handling
Store lyophilized powder under refrigeration (2-8C), protected from heat, light, and moisture. As a short-chain peptide, Livagen is susceptible to proteolytic degradation once reconstituted. Reconstitute immediately before use, keep reconstituted solution refrigerated, and avoid repeated freeze-thaw cycles.
Compliance Notice
Livagen is for laboratory research use only. It is not for human or veterinary use and carries no therapeutic, diagnostic, or clinical indication. This product has not been evaluated by the FDA. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.
